Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Primary periodic paralysis attacks reduced with long-term dichlorphenamide
Key clinical point: Dichlorphenamide effectively reduces attacks of primary periodic paralysis with primarily moderate adverse events in adults.
Major finding: The median weekly PPP attack rate dropped 93.8% in adults receiving dichlorphenamide for 61 weeks and 75% in those receiving it for 52 weeks after 9 weeks placebo.
Study details: A 52-week extension of a 9-week RCT of dichlorphenamide for PPP in 63 adults.
Disclosures: Dr. Johnson has received research support from or consulted with a variety of pharmaceutical companies including Strongbridge Biopharma, the manufacturer of the drug. Other authors consulted for several pharmaceutical companies, and one author is an employee of Strongbridge Biopharma.
Johnson NE et al. AANEM 2019. Abstract 102. Long-term efficacy and adverse event characterization of dichlorphenamide for the treatment of primary periodic paralysis.